Onco-Breastomics: An Eco-Evo-Devo Holistic Approach.

Anca-Narcisa Neagu, Danielle Whitham, Pathea Bruno, Aneeta Arshad, Logan Seymour, Hailey Morrissiey, Angiolina I Hukovic, Costel C Darie
Author Information
  1. Anca-Narcisa Neagu: Laboratory of Animal Histology, Faculty of Biology, "Alexandru Ioan Cuza" University of Ia��i, Carol I bvd. 20A, 700505 Iasi, Romania.
  2. Danielle Whitham: Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY 13699-5810, USA. ORCID
  3. Pathea Bruno: Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY 13699-5810, USA.
  4. Aneeta Arshad: Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY 13699-5810, USA.
  5. Logan Seymour: Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY 13699-5810, USA.
  6. Hailey Morrissiey: Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY 13699-5810, USA.
  7. Angiolina I Hukovic: Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY 13699-5810, USA.
  8. Costel C Darie: Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, Potsdam, NY 13699-5810, USA. ORCID

Abstract

Known as a diverse collection of neoplastic diseases, breast cancer (BC) can be hyperbolically characterized as a dynamic pseudo-organ, a living organism able to build a complex, open, hierarchically organized, self-sustainable, and self-renewable tumor system, a population, a species, a local community, a biocenosis, or an evolving dynamical ecosystem (i.e., immune or metabolic ecosystem) that emphasizes both developmental continuity and spatio-temporal change. Moreover, a cancer cell community, also known as an oncobiota, has been described as non-sexually reproducing species, as well as a migratory or invasive species that expresses intelligent behavior, or an endangered or parasite species that fights to survive, to optimize its features inside the host's ecosystem, or that is able to exploit or to disrupt its host circadian cycle for improving the own proliferation and spreading. BC tumorigenesis has also been compared with the early embryo and placenta development that may suggest new strategies for research and therapy. Furthermore, BC has also been characterized as an environmental disease or as an ecological disorder. Many mechanisms of cancer progression have been explained by principles of ecology, developmental biology, and evolutionary paradigms. Many authors have discussed ecological, developmental, and evolutionary strategies for more successful anti-cancer therapies, or for understanding the ecological, developmental, and evolutionary bases of BC exploitable vulnerabilities. Herein, we used the integrated framework of three well known ecological theories: the Bronfenbrenner's theory of human development, the Vannote's River Continuum Concept (RCC), and the Ecological Evolutionary Developmental Biology (Eco-Evo-Devo) theory, to explain and understand several eco-evo-devo-based principles that govern BC progression. Multi-omics fields, taken together as onco-breastomics, offer better opportunities to integrate, analyze, and interpret large amounts of complex heterogeneous data, such as various and big-omics data obtained by multiple investigative modalities, for understanding the eco-evo-devo-based principles that drive BC progression and treatment. These integrative eco-evo-devo theories can help clinicians better diagnose and treat BC, for example, by using non-invasive biomarkers in liquid-biopsies that have emerged from integrated omics-based data that accurately reflect the biomolecular landscape of the primary tumor in order to avoid mutilating preventive surgery, like bilateral mastectomy. From the perspective of preventive, personalized, and participatory medicine, these hypotheses may help patients to think about this disease as a process governed by natural rules, to understand the possible causes of the disease, and to gain control on their own health.

Keywords

References

  1. Genome Biol Evol. 2021 Dec 1;13(12): [PMID: 34894238]
  2. Elife. 2014 Dec 11;3: [PMID: 25496728]
  3. Cell. 2015 Sep 10;162(6):1229-41 [PMID: 26321679]
  4. Mol Cell Proteomics. 2014 Mar;13(3):836-48 [PMID: 24425749]
  5. Placenta. 2015 Dec;36(12):1412-8 [PMID: 26545962]
  6. Oncogene. 2021 Feb;40(8):1542-1550 [PMID: 33452457]
  7. iScience. 2020 Dec 07;24(1):101901 [PMID: 33364589]
  8. Toxicol Lett. 2011 Aug 10;205(1):15-25 [PMID: 21658437]
  9. Cancers (Basel). 2019 Oct 11;11(10): [PMID: 31614463]
  10. Front Nutr. 2020 Nov 19;7:581388 [PMID: 33330580]
  11. NPJ Breast Cancer. 2021 May 28;7(1):66 [PMID: 34050189]
  12. Parasitology. 2016 Apr;143(5):533-41 [PMID: 26887797]
  13. Genome Biol. 2020 Nov 12;21(1):276 [PMID: 33183336]
  14. Genome Med. 2013 Dec 23;5(12):110 [PMID: 24360023]
  15. Oncol Rep. 2021 Feb;45(2):717-727 [PMID: 33416150]
  16. Nature. 2023 Aug;620(7974):607-614 [PMID: 37495687]
  17. Front Oncol. 2019 Aug 20;9:718 [PMID: 31482062]
  18. Cancer Lett. 2015 Feb 1;357(1):129-140 [PMID: 25444919]
  19. Breast Cancer Res. 2015 Mar 17;17:39 [PMID: 25849111]
  20. Breast Cancer Res Treat. 2015 Jun;151(3):653-60 [PMID: 25975955]
  21. Biochim Biophys Acta. 2015 Feb;1849(2):142-51 [PMID: 24954179]
  22. BMC Evol Biol. 2014 Jul 11;14:155 [PMID: 25011685]
  23. Sci Rep. 2020 Jun 22;10(1):10105 [PMID: 32572125]
  24. Biomedicines. 2023 Jun 27;11(7): [PMID: 37509485]
  25. J Clin Oncol. 2010 Dec 10;28(35):5219-28 [PMID: 20975063]
  26. Int J Mol Sci. 2023 Jul 12;24(14): [PMID: 37511102]
  27. NPJ Precis Oncol. 2018 Feb 16;2(1):4 [PMID: 29872722]
  28. Dev Cell. 2021 Dec 6;56(23):3203-3221.e11 [PMID: 34847378]
  29. Cancers (Basel). 2021 Aug 23;13(16): [PMID: 34439387]
  30. J Theor Biol. 2023 Mar 21;561:111413 [PMID: 36639023]
  31. AIMS Mol Sci. 2020;7(2):82-98 [PMID: 32953979]
  32. Cancer Res. 2020 Feb 1;80(3):613-623 [PMID: 31772037]
  33. Genes (Basel). 2019 Oct 30;10(11): [PMID: 31671657]
  34. Nat Rev Cancer. 2006 Dec;6(12):924-35 [PMID: 17109012]
  35. Int J Mol Sci. 2023 Apr 06;24(7): [PMID: 37047814]
  36. Eur J Epidemiol. 2023 Dec;38(12):1259-1264 [PMID: 36385398]
  37. Infect Genet Evol. 2013 Dec;20:61-70 [PMID: 23954419]
  38. Front Cell Dev Biol. 2022 Mar 01;10:813457 [PMID: 35300412]
  39. Arch Toxicol. 2017 Mar;91(3):1261-1278 [PMID: 27358235]
  40. Int J Mol Sci. 2020 Apr 01;21(7): [PMID: 32244616]
  41. Environ Health. 2020 Nov 17;19(1):117 [PMID: 33203443]
  42. Breast Cancer Res. 2014;16(2):208 [PMID: 25032259]
  43. Nat Commun. 2023 Jun 23;14(1):3742 [PMID: 37353488]
  44. Molecules. 2020 Oct 05;25(19): [PMID: 33027981]
  45. Cell Mol Life Sci. 2023 Aug 10;80(9):244 [PMID: 37561190]
  46. PLoS One. 2010 Jun 23;5(6):e11272 [PMID: 20585605]
  47. Ecol Evol. 2020 Jul 29;10(16):8538-8553 [PMID: 32884638]
  48. Nat Commun. 2023 Sep 19;14(1):5810 [PMID: 37726308]
  49. Biomedicines. 2023 Jun 01;11(6): [PMID: 37371709]
  50. Semin Reprod Endocrinol. 1999;17(3):275-90 [PMID: 10797946]
  51. Exp Hematol Oncol. 2023 Jan 9;12(1):3 [PMID: 36624542]
  52. Cell Commun Signal. 2018 Aug 17;16(1):48 [PMID: 30119678]
  53. Int J Gynaecol Obstet. 2023 Feb;160(2):374-377 [PMID: 36030411]
  54. Curr Breast Cancer Rep. 2013 Sep;5(3): [PMID: 24265860]
  55. Oncotarget. 2017 Apr 25;8(17):27990-27996 [PMID: 28427196]
  56. Int J Environ Res Public Health. 2021 Sep 30;18(19): [PMID: 34639609]
  57. Palliat Med. 2018 Jun;32(6):1078-1090 [PMID: 29457743]
  58. Front Oncol. 2022 May 26;12:860932 [PMID: 35719975]
  59. Adv Exp Med Biol. 2015;846:61-81 [PMID: 25472534]
  60. Nat Rev Genet. 2023 May;24(5):295-313 [PMID: 36494509]
  61. Nutrients. 2020 Feb 18;12(2): [PMID: 32085420]
  62. Evol Appl. 2013 Jan;6(1):46-53 [PMID: 23396634]
  63. Proc Natl Acad Sci U S A. 2019 Jul 9;116(28):14129-14137 [PMID: 31239334]
  64. Front Oncol. 2019 Feb 06;9:43 [PMID: 30788287]
  65. World J Stem Cells. 2015 Oct 26;7(9):1150-84 [PMID: 26516408]
  66. Am J Pathol. 2017 Oct;187(10):2130-2132 [PMID: 28822804]
  67. Sci Rep. 2019 Sep 3;9(1):12684 [PMID: 31481730]
  68. Nat Rev Clin Oncol. 2011 May 31;8(7):444 [PMID: 21629214]
  69. NAR Cancer. 2023 Jun 09;5(3):zcad025 [PMID: 37304756]
  70. Cancer Metastasis Rev. 2019 Jun;38(1-2):149-155 [PMID: 30806853]
  71. Nat Commun. 2020 Oct 28;11(1):5436 [PMID: 33116123]
  72. Am J Stem Cells. 2014 Sep 05;3(2):46-62 [PMID: 25232505]
  73. iScience. 2020 Sep 04;23(9):101531 [PMID: 33083761]
  74. Cancer Epidemiol Biomarkers Prev. 2022 Jan;31(1):85-96 [PMID: 34697058]
  75. Clin Cancer Res. 2014 Jul 1;20(13):3384-9 [PMID: 24756372]
  76. Oncol Lett. 2017 May;13(5):3889-3895 [PMID: 28521486]
  77. Cancers (Basel). 2023 Mar 08;15(6): [PMID: 36980535]
  78. PLoS One. 2015 Dec 14;10(12):e0145061 [PMID: 26661278]
  79. Exp Mol Pathol. 2015 Dec;99(3):617-27 [PMID: 26505174]
  80. Biol Theory. 2018;13(4):228-242 [PMID: 30546273]
  81. Curr Issues Mol Biol. 2021 Oct 10;43(3):1502-1517 [PMID: 34698063]
  82. Evol Appl. 2017 Jul 11;10(10):949-964 [PMID: 29151852]
  83. Clin Proteomics. 2020 May 24;17:16 [PMID: 32489334]
  84. Pharmacol Rep. 2023 Feb;75(1):69-84 [PMID: 36310188]
  85. Nat Ecol Evol. 2017 Nov;1(11):1592-1595 [PMID: 29066812]
  86. Front Pharmacol. 2017 Oct 05;8:699 [PMID: 29051735]
  87. Redox Biol. 2016 Apr;7:30-38 [PMID: 26629949]
  88. Clin Proteomics. 2022 Jul 11;19(1):25 [PMID: 35818030]
  89. Environ Sci Technol. 2023 Aug 22;57(33):12201-12209 [PMID: 37561608]
  90. J Cell Sci. 2017 Feb 15;130(4):663-669 [PMID: 28202602]
  91. Front Cell Infect Microbiol. 2022 Jun 16;12:849022 [PMID: 35782150]
  92. Mol Biol Evol. 2022 Aug 3;39(8): [PMID: 35895848]
  93. Am J Med Genet A. 2013 Nov;161A(11):2788-96 [PMID: 24123833]
  94. Open Biol. 2018 Jun;8(6): [PMID: 29950452]
  95. Environ Int. 2020 Oct;143:105887 [PMID: 32619912]
  96. Int J Surg Pathol. 2007 Oct;15(4):369-75 [PMID: 17913943]
  97. Nat Rev Genet. 2015 Oct;16(10):611-22 [PMID: 26370902]
  98. Genes (Basel). 2018 Aug 09;9(8): [PMID: 30096943]
  99. Environ Health Perspect. 2018 Apr 23;126(4):047011 [PMID: 29687979]
  100. Onco Targets Ther. 2022 Jan 08;15:23-30 [PMID: 35035222]
  101. Cancer Control. 2020 Jan-Dec;27(1):1073274820911058 [PMID: 32129079]
  102. Transl Oncol. 2008 Dec;1(4):158-64 [PMID: 19043526]
  103. Cold Spring Harb Perspect Med. 2014 Apr 01;4(4):a014274 [PMID: 24692189]
  104. Environ Res. 2020 Jul;186:109516 [PMID: 32305677]
  105. Adv Ecol Res. 2019;60:1-24 [PMID: 31908359]
  106. Nat Rev Cancer. 2014 May;14(5):371-80 [PMID: 24739582]
  107. FEBS J. 2017 Oct;284(19):3132-3144 [PMID: 28444969]
  108. J Clin Med. 2021 Aug 08;10(16): [PMID: 34441794]
  109. Am J Pathol. 2019 May;189(5):946-955 [PMID: 30385094]
  110. Int J Mol Sci. 2016 Oct 24;17(10): [PMID: 27783057]
  111. Cells. 2023 Feb 03;12(3): [PMID: 36766853]
  112. Int J Oncol. 2020 Aug;57(2):409-432 [PMID: 32468071]
  113. Front Oncol. 2020 Apr 09;10:476 [PMID: 32328462]
  114. Dev Cell. 2022 Jun 6;57(11):1400-1420.e7 [PMID: 35617956]
  115. Evolution (N Y). 2011 Dec;4(4):624-634 [PMID: 23705033]
  116. Front Immunol. 2021 Aug 31;12:668221 [PMID: 34531851]
  117. Am J Cancer Res. 2021 Sep 15;11(9):4006-4049 [PMID: 34659875]
  118. J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 [PMID: 10599719]
  119. Cancer Metastasis Rev. 2023 Dec;42(4):1201-1218 [PMID: 37540301]
  120. Br J Cancer. 2021 Jan;124(1):1-2 [PMID: 33257840]
  121. Int J Biochem Cell Biol. 2019 Feb;107:140-153 [PMID: 30593953]
  122. Alcohol. 2011 Nov;45(7):689-99 [PMID: 21168302]
  123. Placenta. 2002 Nov;23(10):706-15 [PMID: 12398810]
  124. Gland Surg. 2018 Dec;7(6):611-618 [PMID: 30687632]
  125. Breast Cancer Res. 2020 Nov 13;22(1):125 [PMID: 33187540]
  126. Front Genet. 2019 Mar 01;10:79 [PMID: 30881375]
  127. Cancer Metab. 2020 Jul 10;8:16 [PMID: 32670573]
  128. Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):6406-6411 [PMID: 28484005]
  129. Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):E1343-51 [PMID: 26903627]
  130. Adv Exp Med Biol. 2016;936:93-106 [PMID: 27739044]
  131. Am J Clin Nutr. 2013 Dec;98(6):1493-501 [PMID: 24153343]
  132. Cancer Cell. 2018 Oct 8;34(4):549-560.e9 [PMID: 30300578]
  133. Oncol Lett. 2016 Dec;12(6):4869-4876 [PMID: 28105194]
  134. Surg Today. 2003;33(4):243-8 [PMID: 12707816]
  135. Front Immunol. 2023 Oct 31;14:1297180 [PMID: 38022619]
  136. Oncol Lett. 2020 Dec;20(6):282 [PMID: 33014160]
  137. PLoS Med. 2023 Mar 21;20(3):e1004188 [PMID: 36943819]
  138. Commun Biol. 2019 Aug 8;2:303 [PMID: 31428691]
  139. Syst Biol. 2015 Jan;64(1):e1-25 [PMID: 25293804]
  140. Molecules. 2023 Jun 14;28(12): [PMID: 37375323]
  141. Sultan Qaboos Univ Med J. 2014 May;14(2):e166-9 [PMID: 24790737]
  142. Biophys J. 2018 Nov 20;115(10):2034-2043 [PMID: 30366624]
  143. Front Endocrinol (Lausanne). 2019 Jun 12;10:367 [PMID: 31244777]
  144. Cancer Commun (Lond). 2022 May;42(5):401-434 [PMID: 35481621]
  145. NPJ Breast Cancer. 2021 Mar 11;7(1):26 [PMID: 33707440]
  146. Evol Appl. 2020 Mar 20;13(7):1569-1580 [PMID: 32821273]
  147. J Biol Eng. 2023 Jun 29;17(1):41 [PMID: 37386445]
  148. Evol Appl. 2013 Jan;6(1):1-10 [PMID: 23397042]
  149. Environ Health Perspect. 2021 Mar;129(3):37002 [PMID: 33683140]
  150. Cancers (Basel). 2021 Sep 25;13(19): [PMID: 34638283]
  151. J Appl Toxicol. 2014 Sep;34(9):1041-50 [PMID: 24481588]
  152. Environ Int. 2019 Mar;124:236-248 [PMID: 30658268]
  153. Cancer Res. 2018 Jun 15;78(12):3112-3121 [PMID: 29615433]
  154. J Clin Oncol. 2019 Jul 20;37(21):1800-1809 [PMID: 30995175]
  155. Hereditas. 2018 Nov 3;155:34 [PMID: 30410429]
  156. Front Oncol. 2019 Sep 04;9:765 [PMID: 31555578]
  157. Cell Metab. 2019 Feb 5;29(2):254-267 [PMID: 30581118]
  158. Int J Mol Sci. 2023 Jul 13;24(14): [PMID: 37511145]
  159. Int J Mol Sci. 2021 Aug 07;22(16): [PMID: 34445220]
  160. Breast Cancer Res. 2019 Aug 20;21(1):96 [PMID: 31429809]
  161. Int J Environ Res Public Health. 2022 Feb 08;19(3): [PMID: 35162895]
  162. PLoS One. 2012;7(3):e32923 [PMID: 22470432]
  163. FASEB J. 2020 Jul;34(7):9307-9315 [PMID: 32463148]
  164. Carcinogenesis. 2003 Jan;24(1):1-6 [PMID: 12538342]
  165. Nat Genet. 2019 Sep;51(9):1389-1398 [PMID: 31477929]
  166. Evol Appl. 2011 Mar;4(2):292-314 [PMID: 25567974]
  167. Cancer Control. 2020 Jul-Aug;27(3):1073274820946804 [PMID: 32869651]
  168. Pharmacol Res. 2017 Jan;115:299-308 [PMID: 27939360]
  169. Cancer Discov. 2012 Oct;2(10):881-98 [PMID: 23009760]
  170. J Cell Sci. 2023 Jul 1;136(13): [PMID: 37313743]
  171. Mol Biol Evol. 2020 Feb 1;37(2):320-326 [PMID: 31642480]
  172. Cancers (Basel). 2011 Jun;3(2):1580-92 [PMID: 21776373]
  173. Drug Metab Dispos. 2023 Mar;51(3):350-359 [PMID: 36627162]
  174. Front Genet. 2020 Aug 27;11:829 [PMID: 33193564]
  175. Science. 2021 Oct;374(6563):eabf3066 [PMID: 34591612]
  176. Int J Mol Sci. 2020 Dec 16;21(24): [PMID: 33339353]
  177. J Proteomics. 2016 Mar 1;135:4-11 [PMID: 26453985]
  178. Adv Exp Med Biol. 2014;781:107-25 [PMID: 24277297]
  179. Cell Adh Migr. 2016 May 3;10(3):310-21 [PMID: 27070187]
  180. Cancer Control. 2020 Jan-Dec;27(1):1073274820951776 [PMID: 32942911]
  181. Mol Cancer Res. 2020 Jan;18(1):20-26 [PMID: 31527151]
  182. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11189-94 [PMID: 16847256]
  183. Genome Med. 2020 May 29;12(1):51 [PMID: 32471518]
  184. Annu Rev Public Health. 2018 Apr 1;39:113-133 [PMID: 29328875]
  185. Cancer Res. 2013 May 15;73(10):2965-75 [PMID: 23471846]
  186. Proc Natl Acad Sci U S A. 2021 Mar 16;118(11): [PMID: 33836588]
  187. Comp Biochem Physiol Part D Genomics Proteomics. 2009 Jun;4(2):75-89 [PMID: 20403740]
  188. Front Genet. 2021 Aug 04;12:703541 [PMID: 34422004]
  189. EMBO Mol Med. 2022 Jun 8;14(6):e14283 [PMID: 35506376]
  190. Br J Cancer. 2022 Nov;127(10):1858-1864 [PMID: 36088510]
  191. PeerJ. 2017 Sep 27;5:e3804 [PMID: 28970966]
  192. Life Sci Alliance. 2022 Feb 14;5(5): [PMID: 35165121]
  193. PLoS One. 2014 Mar 17;9(3):e90924 [PMID: 24637948]
  194. J Biomol Tech. 2007 Dec;18(5):277 [PMID: 18166670]
  195. Ann Transl Med. 2022 Mar;10(6):365 [PMID: 35433996]
  196. Trends Ecol Evol. 2022 Jan;37(1):30-41 [PMID: 34579979]
  197. Int J Mol Sci. 2020 Jul 17;21(14): [PMID: 32708855]
  198. PLoS Comput Biol. 2019 Apr 10;15(4):e1006961 [PMID: 30970018]
  199. Genes Dis. 2018 May 12;5(2):77-106 [PMID: 30258937]
  200. Breast Cancer Res. 2021 Apr 6;23(1):44 [PMID: 33823904]
  201. Nat Med. 2015 Jul;21(7):751-9 [PMID: 26099045]
  202. Ann Transl Med. 2014 Nov;2(11):109 [PMID: 25489583]
  203. Breast Cancer Res Treat. 2022 Dec;196(3):483-493 [PMID: 36279023]
  204. Cell Death Differ. 2017 Apr;24(4):575-579 [PMID: 28211873]
  205. ScientificWorldJournal. 2019 Mar 3;2019:4714781 [PMID: 30940992]
  206. Anticancer Res. 2019 Jan;39(1):1-16 [PMID: 30591435]
  207. Cancer Med. 2017 Jul;6(7):1787-1798 [PMID: 28627138]
  208. Bioessays. 2021 Jul;43(7):e2000305 [PMID: 33984158]
  209. Cell Death Discov. 2021 May 14;7(1):104 [PMID: 33990550]
  210. Genes Dev. 2020 Nov 1;34(21-22):1422-1438 [PMID: 33872192]
  211. Cell Stem Cell. 2015 Mar 5;16(3):225-38 [PMID: 25748930]
  212. Front Biosci (Landmark Ed). 2015 Jun 01;20(7):1144-63 [PMID: 25961550]
  213. Nat Commun. 2020 Jun 25;11(1):3213 [PMID: 32587245]
  214. Hum Mol Genet. 2002 Apr 1;11(7):841-51 [PMID: 11929857]
  215. Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1300-1307 [PMID: 31164347]
  216. Elife. 2016 Sep 19;5: [PMID: 27642012]
  217. Nat Commun. 2023 Oct 25;14(1):6796 [PMID: 37880211]
  218. Ecol Evol. 2022 Oct 18;12(10):e9383 [PMID: 36267687]
  219. Epidemiology. 2021 Jul 1;32(4):499-507 [PMID: 33788793]
  220. Int J Cancer. 2019 Aug 15;145(4):962-973 [PMID: 30702160]
  221. Nat Rev Mol Cell Biol. 2010 Jul;11(7):466 [PMID: 20551963]
  222. Mol Cells. 2021 Jul 31;44(7):433-443 [PMID: 34238766]
  223. J Clin Oncol. 2015 Nov 1;33(31):3621-7 [PMID: 26371147]
  224. Curr Biol. 2018 Sep 10;28(17):R976-R980 [PMID: 30205074]
  225. Int J Mol Sci. 2020 Apr 10;21(7): [PMID: 32290245]
  226. Future Oncol. 2013 Nov;9(11):1623-36 [PMID: 24156323]
  227. Oxid Med Cell Longev. 2021 May 18;2021:5572630 [PMID: 34113419]
  228. BMC Evol Biol. 2017 Dec 27;17(1):268 [PMID: 29281983]
  229. Clinics (Sao Paulo). 2021 Jul 16;76:e2837 [PMID: 34287479]
  230. Ann Surg Oncol. 2018 Oct;25(10):2829-2838 [PMID: 29968031]
  231. Cell. 2019 May 16;177(5):1330-1345.e18 [PMID: 30982598]
  232. Theranostics. 2021 Jan 1;11(3):1429-1445 [PMID: 33391543]
  233. Breast Cancer Res. 2020 May 5;22(1):41 [PMID: 32370801]
  234. Mol Cancer. 2020 Nov 24;19(1):165 [PMID: 33234169]
  235. Cancer Res. 2022 Dec 16;82(24):4487-4496 [PMID: 36214625]
  236. Cancer Manag Res. 2020 Oct 29;12:10799-10807 [PMID: 33149685]
  237. Curr Osteoporos Rep. 2017 Aug;15(4):231-238 [PMID: 28597139]
  238. Curr Drug Targets. 2016;17(10):1103-10 [PMID: 26343109]
  239. iScience. 2021 May 11;24(5):102403 [PMID: 34027317]
  240. Int J Mol Sci. 2023 May 11;24(10): [PMID: 37239953]
  241. Med Sci (Basel). 2020 Mar 23;8(1): [PMID: 32210163]
  242. Cold Spring Harb Perspect Med. 2017 Feb 1;7(2): [PMID: 28148564]
  243. Cancer Genet. 2023 Jan;270-271:1-11 [PMID: 36410105]
  244. Evol Appl. 2021 Feb 08;14(4):877-892 [PMID: 33897809]
  245. Biofactors. 2019 Sep;45(5):818-829 [PMID: 31317586]
  246. Front Endocrinol (Lausanne). 2018 Jun 06;9:306 [PMID: 29928262]
  247. Biochem Biophys Res Commun. 2000 Jul 5;273(2):448-53 [PMID: 10873626]
  248. Front Physiol. 2022 Jul 12;13:872562 [PMID: 35903068]
  249. Front Genet. 2023 Aug 17;14:1087432 [PMID: 37662839]
  250. Nat Commun. 2023 Jun 22;14(1):3724 [PMID: 37349288]
  251. Eur J Nutr. 2021 Apr;60(3):1197-1235 [PMID: 33442757]
  252. Toxicol Sci. 2007 Aug;98(2):436-44 [PMID: 17517823]
  253. EMBO J. 2021 Sep 15;40(18):e108389 [PMID: 34459009]
  254. Front Cell Dev Biol. 2019 Mar 07;7:20 [PMID: 30899759]
  255. Biomed Pharmacother. 2021 Jan;133:111016 [PMID: 33246226]
  256. Cancer Metastasis Rev. 1999;18(2):175-80 [PMID: 10728982]
  257. Cancers (Basel). 2022 Jun 21;14(13): [PMID: 35804819]
  258. Front Immunol. 2021 Nov 22;12:768098 [PMID: 34880864]
  259. Crit Rev Oncol Hematol. 2023 Jun;186:103997 [PMID: 37062337]
  260. Theranostics. 2020 Feb 10;10(7):3083-3098 [PMID: 32194856]
  261. J Transl Med. 2021 Mar 25;19(1):124 [PMID: 33766047]
  262. Exposome. 2023 Mar 21;3(1):osad003 [PMID: 37122372]
  263. R Soc Open Sci. 2017 Sep 27;4(9):171060 [PMID: 28989791]
  264. Br J Cancer. 2016 Jan 19;114(2):125-33 [PMID: 26757262]
  265. Cytotechnology. 2020 Oct;72(5):639-647 [PMID: 32572729]
  266. Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):293-298 [PMID: 28870997]
  267. Front Ecol Evol. 2021 Apr;9: [PMID: 34703824]
  268. Biol Rev Camb Philos Soc. 2018 Aug;93(3):1715-1734 [PMID: 29663630]
  269. Int J Mol Sci. 2020 Mar 02;21(5): [PMID: 32121639]
  270. Oxid Med Cell Longev. 2021 Sep 15;2021:4420479 [PMID: 34567408]
  271. Front Oncol. 2023 Jul 25;13:1148861 [PMID: 37564937]
  272. Clin Sci (Lond). 2009 Dec 23;118(7):451-7 [PMID: 20025611]
  273. Biol Reprod. 2011 Sep;85(3):490-7 [PMID: 21636739]
  274. Proc Natl Acad Sci U S A. 2010 Jan 26;107 Suppl 1:1725-30 [PMID: 19805033]
  275. PLoS Genet. 2014 Mar 06;10(3):e1004239 [PMID: 24603726]
  276. MOJ Proteom Bioinform. 2015;2(2):44-57 [PMID: 31360934]
  277. Front Mol Biosci. 2022 Mar 28;9:781111 [PMID: 35419411]
  278. Breast Cancer Res. 2009;11(6):213 [PMID: 19909494]
  279. Sci Total Environ. 2023 Aug 10;885:163946 [PMID: 37149163]
  280. Sci Rep. 2021 Aug 25;11(1):17184 [PMID: 34433859]
  281. J Pathol. 2020 Apr;250(5):612-623 [PMID: 32057095]
  282. Virchows Arch. 2005 Jul;447(1):1-8 [PMID: 15926070]
  283. Nat Commun. 2023 Feb 11;14(1):789 [PMID: 36774358]
  284. Mol Biol Cell. 2011 Jul 15;22(14):2423-35 [PMID: 21613543]
  285. Q Rev Biol. 2006 Sep;81(3):237-58 [PMID: 17051830]
  286. Front Immunol. 2020 May 15;11:933 [PMID: 32670262]
  287. Cancer Commun (Lond). 2022 Jul;42(7):587-608 [PMID: 35642770]
  288. Cancers (Basel). 2020 Dec 14;12(12): [PMID: 33327542]
  289. Transl Oncol. 2021 Jan;14(1):100899 [PMID: 33080522]
  290. Adv Nutr. 2013 Sep 01;4(5):530-2 [PMID: 24038247]
  291. Nature. 2012 Jan 18;481(7381):306-13 [PMID: 22258609]

Grants

  1. R15 CA260126/NCI NIH HHS
  2. R15CA260126/NCI NIH HHS

MeSH Term

Humans
Female
Ecosystem
Breast Neoplasms
Mastectomy
Biological Evolution
Developmental Biology

Word Cloud

Created with Highcharts 10.0.0BCcancerspeciesdevelopmentalecologicalprogressionecosystemalsodiseaseprinciplesevolutionarydatabreastcancharacterizedablecomplextumorcommunityknownwelltumorigenesisdevelopmentmaystrategiesManyunderstandingintegratedtheoryEco-Evo-Devounderstandeco-evo-devo-basedonco-breastomicsbettereco-evo-devotheorieshelppreventiveKnowndiversecollectionneoplasticdiseaseshyperbolicallydynamicpseudo-organlivingorganismbuildopenhierarchicallyorganizedself-sustainableself-renewablesystempopulationlocalbiocenosisevolvingdynamicalieimmunemetabolicemphasizescontinuityspatio-temporalchangeMoreovercelloncobiotadescribednon-sexuallyreproducingmigratoryinvasiveexpressesintelligentbehaviorendangeredparasitefightssurviveoptimizefeaturesinsidehost'sexploitdisrupthostcircadiancycleimprovingproliferationspreadingcomparedearlyembryoplacentasuggestnewresearchtherapyFurthermoreenvironmentaldisordermechanismsexplainedecologybiologyparadigmsauthorsdiscussedsuccessfulanti-cancertherapiesbasesexploitablevulnerabilitiesHereinusedframeworkthreetheories:Bronfenbrenner'shumanVannote'sRiverContinuumConceptRCCEcologicalEvolutionaryDevelopmentalBiologyexplainseveralgovernMulti-omicsfieldstakentogetherofferopportunitiesintegrateanalyzeinterpretlargeamountsheterogeneousvariousbig-omicsobtainedmultipleinvestigativemodalitiesdrivetreatmentintegrativecliniciansdiagnosetreatexampleusingnon-invasivebiomarkersliquid-biopsiesemergedomics-basedaccuratelyreflectbiomolecularlandscapeprimaryorderavoidmutilatingsurgerylikebilateralmastectomyperspectivepersonalizedparticipatorymedicinehypothesespatientsthinkprocessgovernednaturalrulespossiblecausesgaincontrolhealthOnco-Breastomics:HolisticApproach

Similar Articles

Cited By